Paper23282970
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY and 8 others. Am J Surg Pathol, 2013. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Papers, record 23282970. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23282970
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
- PubMed
Topics29
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain Neoplasms | Major topic |
| DNA Modification Methylases | Major topic |
| DNA Repair Enzymes | Major topic |
| Endothelium, Vascular | Major topic |
| Glioblastoma | Major topic |
| Histiocytes | Major topic |
| Tumor Suppressor Proteins | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Antineoplastic Agents, Alkylating | |
| Biomarkers, Tumor | |
| Child | |
| Child, Preschool | |
| DNA Methylation | |
| Dacarbazine | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Predictive Value of Tests | |
| Promoter Regions, Genetic | |
| Staining and Labeling | |
| Survival Rate | |
| Taiwan | |
| Temozolomide | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33710615 | Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/33710615 | PubMed |
| 32320427 | The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. | PLoS One | 2020 | https://conductscience.org/library/papers/32320427 | PubMed |
| 30673883 | Predictive markers for MGMT promoter methylation in glioblastomas. | Neurosurg Rev | 2019 | https://conductscience.org/library/papers/30673883 | PubMed |
| 30500933 | MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. | J Neuropathol Exp Neurol | 2019 | https://conductscience.org/library/papers/30500933 | PubMed |
| 30310321 | An intronic genetic variation of MGMT affects enhancer activity and is associated with glioma susceptibility. | Cancer Manag Res | 2018 | https://conductscience.org/library/papers/30310321 | PubMed |
| 29036186 | The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma. | PLoS One | 2017 | https://conductscience.org/library/papers/29036186 | PubMed |
| 28693158 | Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28693158 | PubMed |
| 26769142 | Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma. | Mod Pathol | 2016 | https://conductscience.org/library/papers/26769142 | PubMed |
| 26538496 | Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. | Target Oncol | 2016 | https://conductscience.org/library/papers/26538496 | PubMed |
| 25575938 | Prognosis of glioblastoma with faint MGMT methylation-specific PCR product. | J Neurooncol | 2015 | https://conductscience.org/library/papers/25575938 | PubMed |
| 25391970 | MGMT promoter methylation in non-neoplastic brain. | J Neurooncol | 2015 | https://conductscience.org/library/papers/25391970 | PubMed |
| 25286040 | Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. | CNS Oncol | 2014 | https://conductscience.org/library/papers/25286040 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23282970
GET https://conductscience.org/api/papers/v1/23282970/authors